Another relevant bsAb, QL1706, which combines an anti-PD-1 antibody with an anti-CTLA-4 antibody, has shown anti-tumor activity in advanced solid tumors, including NSCLC, with an improved tolerability profile due to pharmacokinetic optimization and reduced irAEs [182]. The gene discussed is CTLA4; the disease is neoplasm.